Schmeel FC - Search Results

1

Proton density fat fraction (PDFF) MRI for differentiation of benign and malignant vertebral lesions.

Schmeel FC, Luetkens JA, Wagenhäuser PJ, Meier-Schroers M, Kuetting DL, Feißt A, Gieseke J, Schmeel LC, Träber F, Schild HH, Kukuk GM. Schmeel FC, et al. Among authors: schmeel lc. Eur Radiol. 2018 Jun;28(6):2397-2405. doi: 10.1007/s00330-017-5241-x. Epub 2018 Jan 8. Eur Radiol. 2018. PMID: 29313118

2

Targeting the Wnt/beta-catenin pathway in multiple myeloma.

Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D, Schmidt-Wolf IG. Schmeel LC, et al. Among authors: schmeel fc. Anticancer Res. 2013 Nov;33(11):4719-26. Anticancer Res. 2013. PMID: 24222106

3

Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.

Schmeel FC, Schmeel LC, Kim Y, Schmidt-Wolf IG. Schmeel FC, et al. Among authors: schmeel lc. Hematol Oncol. 2014 Dec;32(4):197-204. doi: 10.1002/hon.2122. Epub 2014 Jan 27. Hematol Oncol. 2014. PMID: 24470348

4

Targeting the Wnt/beta-catenin pathway in renal cell carcinoma.

Von Schulz-Hausmann SA, Schmeel LC, Schmeel FC, Schmidt-Wolf IG. Von Schulz-Hausmann SA, et al. Among authors: schmeel lc, schmeel fc. Anticancer Res. 2014 Aug;34(8):4101-8. Anticancer Res. 2014. PMID: 25075035

5

Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.

Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IG. Schmeel FC, et al. Among authors: schmeel lc. Int J Mol Sci. 2014 Aug 21;15(8):14632-48. doi: 10.3390/ijms150814632. Int J Mol Sci. 2014. PMID: 25196601 Free PMC article. Review.

6

Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).

Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG. Schmeel LC, et al. Among authors: schmeel fc. J Cancer Res Clin Oncol. 2015 May;141(5):839-49. doi: 10.1007/s00432-014-1864-3. Epub 2014 Nov 8. J Cancer Res Clin Oncol. 2015. PMID: 25381063

7

In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.

Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, Endo T, Schmidt-Wolf IG. Schmeel LC, et al. Among authors: schmeel fc. Anticancer Res. 2015 Feb;35(2):835-41. Anticancer Res. 2015. PMID: 25667464

8

Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells.

Schmeel LC, Schmeel FC, Kim Y, Blaum-Feder S, Endo T, Schmidt-Wolf IG. Schmeel LC, et al. Among authors: schmeel fc. Anticancer Res. 2015 Mar;35(3):1369-76. Anticancer Res. 2015. PMID: 25750287

9

Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.

Stöhr E, Schmeel FC, Schmeel LC, Hänel M, Schmidt-Wolf IG; German Refractory Myeloma Study Group. Stöhr E, et al. Among authors: schmeel lc, schmeel fc. J Cancer Res Clin Oncol. 2015 Dec;141(12):2205-12. doi: 10.1007/s00432-015-2014-2. Epub 2015 Jul 9. J Cancer Res Clin Oncol. 2015. PMID: 26156122

10

In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.

Schmeel LC, Schmeel FC, Blaum-Feder S, Schmidt-Wolf IG. Schmeel LC, et al. Among authors: schmeel fc. Anticancer Res. 2015 Nov;35(11):5921-6. Anticancer Res. 2015. PMID: 26504016

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters